GlassScriptPhysician profile
Cameron S Sikavi
NPI 1114303302
$7,796.19
in general payments reported to CMS, 2019-2025
41 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $335 · 2021: $512 · 2022: $1,050 · 2023: $1,791 · 2024: $1,650 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,206 · Education: $23.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.76 |
| Education | $23.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,401.52 | 2021-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $667.83 | 2023-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $664.71 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $569.75 | 2020-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $539.69 | 2019-2025 | |
| Janssen Biotech, INC. | $507.93 | 2022-2025 | Tremfya, Stelara, Simponi |
| Boston Scientific Corporation | $386.95 | 2021 | |
| Capsovision, INC. | $365.64 | 2025 | Capsocam Plus |
| Cook Medical LLC | $292.43 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $235.59 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $230.35 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.11 | 2022-2023 | Lifevest |
| Celgene Corporation | $188.61 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $141.85 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $134.03 | 2023-2024 | Dificid, Verquvo |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Sikavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.